{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:07:27Z","timestamp":1788516447026,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC 19075"],"award-info":[{"award-number":["MC_PC 19075"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two doses of ChAdOx or 1.6\u2009m with BNT162b2. The incidence rate ratio (IRR) for idiopathic thrombocytopenic purpura (ITP) 14\u201320 days post-ChAdOx1 second dose was 2.14, 95% confidence interval (CI) 0.90\u20135.08. The incidence of ITP post-second dose ChAdOx1 was 0.59 (0.37\u20130.89) per 100,000 doses. No evidence of an increased risk of CVST was found for the 0\u201327 day risk period (IRR 0.83, 95% CI 0.16 to 4.26). However, few (\u22645) events arose within this risk period. It is perhaps noteworthy that these events all clustered in the 7\u201313 day period (IRR 4.06, 95% CI 0.94 to 17.51). No other associations were found for second dose ChAdOx1, or any association for second dose BNT162b2 vaccination. Second dose ChAdOx1 vaccination was associated with increased borderline risks of ITP and CVST events. However, these events were rare thus providing reassurance about the safety of these vaccines. Further analyses including more cases are required to determine more precisely the risk profile for ITP and CVST after a second dose of ChAdOx1 vaccine.<\/jats:p>","DOI":"10.1038\/s41467-022-32264-6","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T15:09:28Z","timestamp":1660576168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5194-8083","authenticated-orcid":false,"given":"Colin R.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-9092","authenticated-orcid":false,"given":"Srinivasa Vittal","family":"Katikireddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"McCowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis D.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-856X","authenticated-orcid":false,"given":"Sarah J.","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Rudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-526X","authenticated-orcid":false,"given":"Ruby S. M.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-2641","authenticated-orcid":false,"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. D. Richard","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0814-0801","authenticated-orcid":false,"given":"Ashley","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-000X","authenticated-orcid":false,"given":"Ronan A.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-3056","authenticated-orcid":false,"given":"Aziz","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"32264_CR1","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 373, n1088 (2021).","journal-title":"BMJ"},{"key":"32264_CR2","doi-asserted-by":"crossref","unstructured":"Vasileiou, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397, 1646\u20131657 (2021).","DOI":"10.1016\/S0140-6736(21)00677-2"},{"key":"32264_CR3","doi-asserted-by":"publisher","first-page":"e014200","DOI":"10.1136\/bmjopen-2016-014200","volume":"7","author":"CR Simpson","year":"2017","unstructured":"Simpson, C. R. et al. Evaluating the effectiveness, impact and safety of live attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. BMJ Open 7, e014200 (2017).","journal-title":"BMJ Open"},{"key":"32264_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"32264_CR5","unstructured":"GOV.UK. COVID-19 mRNA vaccine BNT162b2 product information sheet, <https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/967861\/Temporary_Authorisation_HCP_Information_BNT162_7_0_UK_.pdf (2020)."},{"key":"32264_CR6","unstructured":"Australian Government Department of Health. COVID-19 vaccine weekly safety report\u201408-07-2021, https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report-08-07-2021 (2021)."},{"key":"32264_CR7","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384, 2092\u20132101 (2021).","journal-title":"N. Engl. J. Med."},{"key":"32264_CR8","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz, N. H. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2124\u20132130 (2021).","journal-title":"N. Engl. J. Med."},{"key":"32264_CR9","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","volume":"384","author":"M Scully","year":"2021","unstructured":"Scully, M. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2202\u20132211 (2021).","journal-title":"N. Engl. J. Med."},{"key":"32264_CR10","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S1473-3099(18)30786-2","volume":"19","author":"CR Simpson","year":"2019","unstructured":"Simpson, C. R. et al. The UK\u2019s pandemic influenza research portfolio: a model for future research on emerging infections. Lancet Infect. Dis. 19, e295\u2013e300 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"32264_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1473-3099(20)30398-4","volume":"20","author":"CR Simpson","year":"2020","unstructured":"Simpson, C. R. et al. The UK hibernated pandemic influenza research portfolio: triggered for COVID-19. Lancet Infect. Dis. 20, 767\u2013769 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"32264_CR12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41591-021-01408-4","volume":"27","author":"CR Simpson","year":"2021","unstructured":"Simpson, C. R. et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat. Med. 27, 1290\u20131297 (2021).","journal-title":"Nat. Med."},{"key":"32264_CR13","unstructured":"European Medicines Agency. COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB, https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-6-october-2021_en.pdf (2021)."},{"key":"32264_CR14","doi-asserted-by":"publisher","first-page":"n1931","DOI":"10.1136\/bmj.n1931","volume":"374","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox, J. et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ 374, n1931 (2021).","journal-title":"BMJ"},{"key":"32264_CR15","doi-asserted-by":"publisher","first-page":"n1114","DOI":"10.1136\/bmj.n1114","volume":"373","author":"A Potteg\u00e5rd","year":"2021","unstructured":"Potteg\u00e5rd, A. et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ 373, n1114 (2021).","journal-title":"BMJ"},{"key":"32264_CR16","doi-asserted-by":"publisher","first-page":"e1003927","DOI":"10.1371\/journal.pmed.1003927","volume":"19","author":"S Kerr","year":"2022","unstructured":"Kerr, S. et al. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales. PLOS Med. 19, e1003927 (2022).","journal-title":"PLOS Med."},{"key":"32264_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jama.2021.21699","volume":"327","author":"MJ Jabagi","year":"2022","unstructured":"Jabagi, M. J. et al. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older. JAMA 327, 80\u201382 (2022).","journal-title":"JAMA"},{"key":"32264_CR18","doi-asserted-by":"publisher","first-page":"e039097","DOI":"10.1136\/bmjopen-2020-039097","volume":"10","author":"CR Simpson","year":"2020","unstructured":"Simpson, C. R. et al. Early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data. BMJ Open 10, e039097 (2020).","journal-title":"BMJ Open"},{"key":"32264_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06960-5","volume":"21","author":"PM McKeigue","year":"2021","unstructured":"McKeigue, P. M. et al. Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland. BMC Infect. Dis. 21, 1275 (2021).","journal-title":"BMC Infect. Dis."},{"key":"32264_CR20","unstructured":"Royal College of General Practitioners. GP Summary Component of the NHS Summary Care Record. https:\/\/www.scimp.scot.nhs.uk\/wp-content\/uploads\/documents\/RCGP_SCR__Final_dated.pdf (2007)."},{"key":"32264_CR21","unstructured":"Public Health Scotland. SMR Timeliness. https:\/\/www.isdscotland.org\/products-and-Services\/Data-Support-and-Monitoring\/SMR-Timeliness\/ (2021)."},{"key":"32264_CR22","unstructured":"UK Government. COVID-19: the green book, chapter 14a. https:\/\/www.gov.uk\/government\/publications\/covid-19-the-green-book-chapter-14a (2022)."},{"key":"32264_CR23","unstructured":"National Services Scotland. National Data Catalogue. Rapid Preliminary Inpatient Data (RAPID), https:\/\/www.ndc.scot.nhs.uk\/National-Datasets\/data.asp?SubID=37 (2020)."},{"key":"32264_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"32264_CR25","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"32264_CR26","unstructured":"Paul Ehrlich Institut. COVID-19 Vac\u00adcine As\u00adtraZeneca\u2014Safe\u00adty As\u00adsess\u00adment Re\u00adsult: The Vac\u00adcine is Safe and Ef\u00adfec\u00adtive in the Fight against COVID-19, https:\/\/www.pei.de\/EN\/newsroom\/hp-news\/2021\/210319-covid-19-vaccine-astrazeneca-safety-assessment-result-vaccine-safe-and-effective.html (2021)."},{"key":"32264_CR27","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jclinepi.2005.11.012","volume":"59","author":"JM Glanz","year":"2006","unstructured":"Glanz, J. M. et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J. Clin. Epidemiol. 59, 808\u2013818 (2006).","journal-title":"J. Clin. Epidemiol."},{"key":"32264_CR28","unstructured":"R Code Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2020)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32264-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32264-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32264-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:25:43Z","timestamp":1669314343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32264-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32264"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32264-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"27 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S. is a member of the Scottish Government Chief Medical Officer\u2019s COVID-19 Advisory Group and its Standing Committee on Pandemics; the UK Government\u2019s New and Emerging Respiratory Virus Threats (NERVTAG) Risk Stratification Subgroup; and was a member of AstraZeneca\u2019s COVID-19 Thrombocytopenia Taskforce. All roles are remunerated to A.S. or his institution. C.R.S. declares funding from the MRC, NIHR, CSO, and New Zealand Ministry for Business, Innovation and Employment and Health Research Council during the conduct of this study. SVK is co-chair of the Scottish Government\u2019s Expert Reference Group on COVID-19 and ethnicity, is a member of the Scientific Advisory Group on Emergencies (SAGE) subgroup on ethnicity and acknowledges funding from a NRS Senior Clinical Fellowship\u00a0(SCAF\/15\/02), MRC (MC_UU_00022\/2) and CSO\u00a0(SPHSU17). C.R. is a member of the Scottish Government Chief Medical Officer\u2019s COVID-19 Advisory Group, SPI-M, MHRA Vaccine Benefit and Risk Working Group. All other authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4800"}}